MedPath

TO KNOW THE AMOUNT OF CANINE MOVEMENT AFTER LOCAL INJECTION OF INJECTIBLE PLATELET RICH FIBRIN.

Phase 4
Conditions
Health Condition 1: 3- AdministrationHealth Condition 2: K03- Other diseases of hard tissues ofteeth
Registration Number
CTRI/2024/04/065362
Lead Sponsor
Dr Nikita Navgire
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Class I bimax cases requiring first premolar extraction with absolute anchorage.

2.Class II crowding cases requiring first premolar extraction with absolute anchorage.

3.Class II division 1, camouflage cases requiring first premolar extraction with absolute anchorage.

Exclusion Criteria

1.Patients with bone metabolic and blood disorders.

2.Patients with mental disability.

3.Patients with congenital deformity of Oro-Facial structures.

4.Chronic ulcers in oral cavity.

5.Chronic Periodontitis.

6.Facial asymmetry

7.Patients with systemic or chronic debilitating disease that could interfere with bone remodeling.

8.Patients on long-term systemic corticosteroids, calcium channel blockers, antibiotics, bisphosphonates. Or any other medications that could adversely affect the development of the jaws and teeth and subsequent tooth movement.

9.Patients with craniofacial deformities

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Acceleration of orthodontic tooth movement and thus reduction in treatment duration.Timepoint: T0- at baseline <br/ ><br>T1- at 30 days <br/ ><br>T2- at 60 days <br/ ><br>T3- at 90 days <br/ ><br>T4- at 120 days <br/ ><br>T5- at 150 days <br/ ><br>T6- at 180 days.
Secondary Outcome Measures
NameTimeMethod
ACHIEVING SPACE CLOSURETimepoint: T0- at baseline <br/ ><br>T1- at 30 days <br/ ><br>T2- at 60 days <br/ ><br>T3- at 90 days <br/ ><br>T4- at 120 days <br/ ><br>T5- at 150 days <br/ ><br>T6- at 180 days.
© Copyright 2025. All Rights Reserved by MedPath